For the quarter ending 2025-06-30, IRME had -$66K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-06-30 |
|---|---|
| Stock based compensation | 141 |
| Loss for the period | -1,474 |
| Decrease in accounts receivable | -49 |
| Decrease in trade and other payables | -10 |
| Depreciation | 7 |
| Non-cash financial expenses (income) | -933 |
| Increase in deferred grant income | 173 |
| Net cash used in operating activities | -181 |
| Repayment of short-term loan | 39 |
| Proceeds from short-term loan | 39 |
| Proceeds from private placement of common stock and warrants. (see also note 4.8) | 88 |
| Issuance of convertible loans | 31 |
| Net cash provided by financing activities | 119 |
| Effect of exchange rate changes on cash and cash equivalents | -4 |
| Net decrease in cash and cash equivalents | -66 |
IR-Med, Inc. (IRME)
IR-Med, Inc. (IRME)